Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNKABH)

Drug Name	PMID29671355-Compound-11 Drug Info
Cross-matching ID	PubChem CID 118005782 TTD Drug ID DMNKABH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histone deacetylase 3 (HDAC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CHR-3996	DMIXPNG	Lymphoma	2A80-2A86	Phase 1/2	[2]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-61	DMXH1G3	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 6 (HDAC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Citarinostat	DMQLODU	Multiple myeloma	2A83	Phase 1	[3]
KA2507	DMW0H9Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 2 (HDAC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CHR-3996	DMIXPNG	Lymphoma	2A80-2A86	Phase 1/2	[2]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[4]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[5]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[4]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[6]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[7]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[9]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[10]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[4]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[1]
Histone deacetylase 2 (HDAC2)	TTSHTOI	HDAC2_HUMAN	Inhibitor	[1]
Histone deacetylase 3 (HDAC3)	TT4YWTO	HDAC3_HUMAN	Inhibitor	[1]
Histone deacetylase 6 (HDAC6)	TT5ZKDI	HDAC6_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
2	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
5	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
8	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
9	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
10	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
11	2011 Pipeline of 4SC AG.